- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about SNY
Recent news which mentions SNY
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
From Benzinga
From Benzinga
Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program
October 07, 2021
From Benzinga
Allowing people to mix COVID-19 vaccines could cut into Pfizer and Moderna’s revenue next year
October 06, 2021
From MarketWatch
3 Biotech Stocks That Surged in September
October 05, 2021
From Motley Fool
From Motley Fool
Here's a High-Yield Dividend Stock Wall Street Thinks Could Jump 26% Within 12 Months
October 04, 2021
From Motley Fool
This Healthcare Company Is Using AI to Develop Drugs
October 03, 2021
From Motley Fool
From Benzinga
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
September 30, 2021
From Motley Fool
Can These Former Biotech Growth Stocks Regain Their Form?
September 29, 2021
From Motley Fool
Hopes rise that Pfizer COVID-19 vaccine will be authorized for use in children aged 5 to 11 by late October, and Russia suffers worst one-day death toll
September 28, 2021
From MarketWatch
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
From Benzinga
Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know
September 28, 2021
From Benzinga
3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%
September 28, 2021
From Motley Fool
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
September 27, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
September 27, 2021
From Benzinga
3 Top Biotech Stocks to Buy for the Long Haul
September 27, 2021
From Motley Fool
Acceleron In Advanced $11B Buyout Talks: Bloomberg
September 27, 2021
From Benzinga
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
September 20, 2021
From Benzinga
Here's Why Moderna's Stock Could Crash Before the End of 2021
September 19, 2021
From Motley Fool
5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch
September 18, 2021
From Motley Fool
AbbVie's Pain Is Sanofi's and Regeneron's Gain
September 18, 2021
From Motley Fool
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
September 12, 2021
From Benzinga
These Promising Clinical Results Could Be Huge for Amgen Investors
September 11, 2021
From Motley Fool
Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?
September 11, 2021
From Motley Fool
3 Stocks to Watch in September
September 10, 2021
From Motley Fool
Could This Be Pfizer's Next Blockbuster Vaccine?
September 10, 2021
From Motley Fool
EMA Gives Nod To Additional Sites For Pfizer - BioNTech COVID-19 Vaccine
September 09, 2021
From Benzinga
Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders?
September 09, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.